Pediatric Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Eur J Pediatr. 2021 Sep;180(9):2889-2895. doi: 10.1007/s00431-021-04060-9. Epub 2021 Apr 4.
The study aimed to evaluate the plasma copeptin levels in children with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), to assess the predictive value of plasma copeptin level for adverse outcomes, and to correlate its levels with various data in these patients. We included 25 children with PAH-CHD as group I and 25 children with CHD and no PAH as group II. Twenty-five healthy children of matched age and sex served as the control group. Patients were evaluated by echocardiography and right heart catheterization. The plasma level of copeptin was also measured. All patients were followed up for death or readmission for 1 year. Plasma copeptin levels were significantly higher in group I compared to group II and the control group and were correlated with increasing severity of PAH. The best cutoff of plasma copeptin level to predict poor prognosis in group I was ≥24.2 ng/ml with a sensitivity of 90% and a specificity of 80%. There was a statistically significant positive correlation between plasma copeptin levels and mean pulmonary pressure, pulmonary vascular resistance, and pulmonary blood flow, while there was a statistically significant negative correlation between plasma copeptin levels and right ventricular diastolic function.Conclusion: Plasma copeptin levels are elevated in children with PAH-CHD and found to be a good predictive marker for the severity of PAH and poor prognosis in these children. What is Known: •PH is a life-threatening condition that can lead to right ventricular failure and death. •We need a non-invasive easy biomarker that can identify PH children with unfavorable prognosis who needed further intervention. What is New: •It is the first study that assessed the prognostic value of plasma copeptin levels in children with PAH-CHD. •We found that copeptin is an accurate dependable biomarker for predicting poor outcomes in children with PAH-CHD who needed extensive further intervention.
本研究旨在评估与先天性心脏病相关的肺动脉高压(PAH-CHD)患儿的血浆 copeptin 水平,评估血浆 copeptin 水平对不良结局的预测价值,并将其与这些患者的各种数据相关联。我们纳入了 25 例 PAH-CHD 患儿作为 I 组,25 例无 PAH 的 CHD 患儿作为 II 组。25 名年龄和性别相匹配的健康儿童作为对照组。通过超声心动图和右心导管检查对患者进行评估。还测量了血浆 copeptin 水平。所有患者均进行了 1 年的死亡或再次入院随访。I 组患者的血浆 copeptin 水平明显高于 II 组和对照组,且与 PAH 严重程度呈正相关。I 组预测预后不良的最佳血浆 copeptin 水平截断值为≥24.2ng/ml,其灵敏度为 90%,特异性为 80%。血浆 copeptin 水平与平均肺动脉压、肺血管阻力和肺血流量呈正相关,与右心室舒张功能呈负相关。结论:PAH-CHD 患儿的血浆 copeptin 水平升高,且发现其是预测 PAH 严重程度和患儿不良预后的良好预测指标。已知:•PH 是一种危及生命的疾病,可导致右心衰竭和死亡。•我们需要一种非侵入性的简单生物标志物,能够识别出预后不良的 PH 患儿,需要进一步干预。新发现:•这是第一项评估血浆 copeptin 水平在 PAH-CHD 患儿中的预后价值的研究。•我们发现 copeptin 是预测 PAH-CHD 患儿不良结局的一种准确可靠的生物标志物,这些患儿需要广泛的进一步干预。